Stay updated with breaking news from Clearside Biomedical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Free Report) have been given an average recommendation of “Buy” by the four brokerages that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have covered the stock in the […]
/PRNewswire/ -- DelveInsight's Stargardt Disease Market Insights report includes a comprehensive understanding of current treatment practices, Stargardt...
/PRNewswire/ -- DelveInsight's Dry Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment...
Clearside Biomedical (NASDAQ:CLSD – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a note issued to investors on Thursday, Benzinga reports. They presently have a $4.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 222.58% from […]